Sign In
Buy JYNT
The Joint Earnings Calls
| Release date | Nov 06, 2025 |
| EPS estimate | -$0.0100 |
| EPS actual | $0.0200 |
| EPS Surprise | 300.00% |
| Revenue estimate | 14.294M |
| Revenue actual | 13.381M |
| Revenue Surprise | -6.39% |
| Release date | Aug 07, 2025 |
| EPS estimate | -$0.0700 |
| EPS actual | -$0.0600 |
| EPS Surprise | 14.29% |
| Revenue estimate | 13.36M |
| Revenue actual | 13.27M |
| Revenue Surprise | -0.672% |
| Release date | May 08, 2025 |
| EPS estimate | -$0.0200 |
| EPS actual | -$0.0300 |
| EPS Surprise | -50.00% |
| Revenue estimate | 13.021M |
| Revenue actual | 13.078M |
| Revenue Surprise | 0.435% |
| Release date | Mar 13, 2025 |
| EPS estimate | $0.0600 |
| EPS actual | $0.0600 |
| Revenue estimate | 28.991M |
| Revenue actual | 14.447M |
| Revenue Surprise | -50.17% |
Last 4 Quarters for The Joint
Below you can see how JYNT performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Mar 13, 2025 |
| Price on release | $10.54 |
| EPS estimate | $0.0600 |
| EPS actual | $0.0600 |
| Date | Price |
|---|---|
| Mar 07, 2025 | $10.98 |
| Mar 10, 2025 | $10.79 |
| Mar 11, 2025 | $10.49 |
| Mar 12, 2025 | $10.52 |
| Mar 13, 2025 | $10.54 |
| Mar 14, 2025 | $11.02 |
| Mar 17, 2025 | $11.02 |
| Mar 18, 2025 | $11.30 |
| Mar 19, 2025 | $12.43 |
| 4 days before | -4.01% |
| 4 days after | 17.93% |
| On release day | 4.55% |
| Change in period | 13.21% |
| Release date | May 08, 2025 |
| Price on release | $10.53 |
| EPS estimate | -$0.0200 |
| EPS actual | -$0.0300 |
| EPS surprise | -50.00% |
| Date | Price |
|---|---|
| May 02, 2025 | $10.50 |
| May 05, 2025 | $9.90 |
| May 06, 2025 | $9.85 |
| May 07, 2025 | $9.94 |
| May 08, 2025 | $10.53 |
| May 09, 2025 | $9.99 |
| May 12, 2025 | $10.12 |
| May 13, 2025 | $10.09 |
| May 14, 2025 | $9.98 |
| 4 days before | 0.286% |
| 4 days after | -5.22% |
| On release day | -5.13% |
| Change in period | -4.95% |
| Release date | Aug 07, 2025 |
| Price on release | $10.70 |
| EPS estimate | -$0.0700 |
| EPS actual | -$0.0600 |
| EPS surprise | 14.29% |
| Date | Price |
|---|---|
| Aug 01, 2025 | $10.93 |
| Aug 04, 2025 | $11.18 |
| Aug 05, 2025 | $11.19 |
| Aug 06, 2025 | $11.13 |
| Aug 07, 2025 | $10.70 |
| Aug 08, 2025 | $10.74 |
| Aug 11, 2025 | $10.80 |
| Aug 12, 2025 | $11.08 |
| Aug 13, 2025 | $11.01 |
| 4 days before | -2.10% |
| 4 days after | 2.90% |
| On release day | 0.374% |
| Change in period | 0.732% |
| Release date | Nov 06, 2025 |
| Price on release | $7.98 |
| EPS estimate | -$0.0100 |
| EPS actual | $0.0200 |
| EPS surprise | 300.00% |
| Date | Price |
|---|---|
| Oct 31, 2025 | $7.89 |
| Nov 03, 2025 | $7.87 |
| Nov 04, 2025 | $7.89 |
| Nov 05, 2025 | $8.29 |
| Nov 06, 2025 | $7.98 |
| Nov 07, 2025 | $7.67 |
| Nov 10, 2025 | $7.81 |
| Nov 11, 2025 | $8.15 |
| Nov 12, 2025 | $8.35 |
| 4 days before | 1.14% |
| 4 days after | 4.64% |
| On release day | -3.88% |
| Change in period | 5.83% |
The Joint Earnings Call Transcript Summary of Q3 2025
The Joint Corp. reported Q3 2025 results showing modest top-line growth and meaningful margin improvement as the company accelerates its transition to a pure-play franchisor. Revenue from continuing operations rose 6% while consolidated adjusted EBITDA increased 36% driven by cost rightsizing and refranchising activity. System-wide sales were down 1.5% and comp sales declined 2%, with lower new patient counts cited as the primary sales shortfall. Management is addressing this through a national brand refresh focused on pain relief, stronger digital/SEO efforts, a new mobile app rollout, and a 3-tier pricing pilot for wellness plans. The company has an initial agreement to sell 45 corporate clinics (Southern California) and is negotiating for 33 more, aiming to complete refranchising despite lender-related timing headwinds. Liquidity is healthy ($29.7M cash), the board authorized an additional $12M buyback, and guidance was narrowed: system-wide sales $530–534M, comps -1% to flat, consolidated adjusted EBITDA maintained at $10.8–11.8M. Management expects 2026 continuing operations to be more profitable than 2025 as refranchising and SG&A reductions take effect, with Q4 call to include 2026 guidance and details of the fully franchised model.
